Inhibikase Therapeutics, Inc. (IKT) vs Rocket Pharmaceuticals, Inc. (RCKT)
A side-by-side comparison of Inhibikase Therapeutics, Inc. and Rocket Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IKT
Inhibikase Therapeutics, Inc.
$1.99HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
RCKT
Rocket Pharmaceuticals, Inc.
$2.48HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — IKT vs RCKT
growth of $100 · dividends reinvested · last 6yIKT -96.6% (-43.2%/yr)RCKT -95.6% (-40.5%/yr)RCKT compounded faster over this window
IKT RCKT
IKT vs RCKT: by the numbers
- •RCKT is the larger company ($270M vs $263M market cap).
Metrics side by side
Valuation
| Metric | IKT | RCKT |
|---|---|---|
| P/B ratio | 1.71 | 0.73 |
Profitability
| Metric | IKT | RCKT |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -39.55% | -4.68% |
| ROIC | -42.92% | -48.92% |
Growth (annualized)
| Metric | IKT | RCKT |
|---|---|---|
| Total return CAGR (5Y) | -29.10% | -38.33% |
Frequently asked
- How have IKT and RCKT total returns compared?
- Over the past 5 years, IKT delivered -29.10% and RCKT delivered -38.33% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.